We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Open Drawer MenuClose Drawer Menu
Bioanalysis
BioTechniques
Future Drug Discovery
Future Medicinal Chemistry
Future Science OA
International Journal of Pharmacokinetics
Pharmaceutical Patent Analyst
Therapeutic Delivery
Special Report

Device factors affecting pulmonary delivery of dry powders

    Chad C Smutney

    * Author for correspondence

    MannKind Corp, One Casper St, Danbury CT 06810, USA.

    Search for more papers by this author

    Email the corresponding author at CSmutney@mannkindcorp.com

    ,
    Marshall Grant

    MannKind Corp, One Casper St, Danbury CT 06810, USA

    Search for more papers by this author

    ,
    P Spencer Kinsey

    MannKind Corp, One Casper St, Danbury CT 06810, USA

    Search for more papers by this author

    Published Online:7 Aug 2013https://doi.org/10.4155/tde.13.77

    Abstract

    The use of orally inhaled dry powder technologies is one way of delivering medicines to the lung for treating local conditions or for achieving systemic effect. These involve dry powder formulations containing an active pharmaceutical ingredient together with inhaler devices. These powder/device systems enable patients to inhale and aerosolize the medicine into suitably sized particles that deposit in the lung. Several inhaler centric aspects of these delivery systems are presented and discussed in context of new product development. Case examples are provided to highlight several inhaler aspects and to guide development of powder/inhaler systems.

    Papers of special note have been highlighted as: ▪ of interest

    References

    • 1  Patton JS. The lungs as a portal of entry for systemic drug delivery. Proc. Am. Thorac. Soc.1,338–344 (2004).
      Medline CASGoogle Scholar
    • 2  Ashish AK. Pulmonary drug delivery system. Int. J. Pharm. Tech. Res.4(1),293–305 (2012).
      Google Scholar
    • 3  Labiris NR. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol.56(6),588–599 (2003).
      Medline CASGoogle Scholar
    • 4  Frijlink HW. Dry-powder inhalers for pulmonary drug delivery. Expert Opin. Drug Deliv.1(1),67–86 (2004).▪ Patient work associated with use of high-resistance inhalers is described.
      Medline CASGoogle Scholar
    • 5  Pfutzner A. Technosphere/insulin – a new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technol. Ther.4(5),589–594 (2002).
      MedlineGoogle Scholar
    • 6  Donovan MJ. Dry-powder inhaler device influence on carrier particle performance. J. Pharm. Sci.101(3),1097–1107 (2012).
      Medline CASGoogle Scholar
    • 7  de Boer AH. Air classifier technology (ACT) in dry powder inhalation part 1. Introduction of a novel force distribution concept (FDC) explaining the performance of a basic air classifier on adhesive mixtures. Int. J. Pharm.260,187–200 (2003).
      Medline CASGoogle Scholar
    • 8  Telko MJ. Dry-powder inhaler formulation. Respir. Care50(9),1209–1227 (2005).▪ Description of particle sizes required for lung deposition and use of engineered particles.
      MedlineGoogle Scholar
    • 9  Geller DE. Development of an inhaled dry-powder formulation of tobramycin using pulmosphere technology. J. Aersol Med. Pulm. Drug Deliv.24(4),175–182 (2011).▪ Engineered particles and the ability to make dispersible powders are described.
      Medline CASGoogle Scholar
    • 10  Koushik K. Particle & device engineering for inhalation drug delivery. Drug Develop. Deliv.4(2),2–5 (2004).
      Google Scholar
    • 11  Chow AH, Tong HH, Chattopadhyay P, Shekunov BY. Particle engineering for pulmonary drug delivery. Pharm. Res.24(3),411–437 (2007).
      Medline CASGoogle Scholar
    • 12  Mitchell J. In vitro and in vivo aspects of cascade impactor tests and inhaler perfomance: a review. AAPS PharmSciTech8(4),237–248 (2007).
      Google Scholar
    • 13  Mitchell JP. Laser diffractometry as a technique for the rapid assessment of aerosol particle size from inhalers. J. Aerosol Med.19(4),409–433 (2006).▪ Difficulties in establishing an in vitro–in vivo correlation using inertial impaction testing is discussed.
      Medline CASGoogle Scholar
    • 14  de Boer AH. Inhalation characteristics and their effects on in vitro drug delivery from Dry-powder inhalers part 1. Inhalation characteristics, work of breathing and volunteers’ preference in dependence of the inhalers resistance. Int. J. Pharm.130,231–244 (1996).
      CASGoogle Scholar
    • 15  Smutney CC. Inspiratory efforts achieved in use of the technosphere insulin inhalation system. J. Diabetes Sci. Technol.3(5),1175–1182 (2009).
      MedlineGoogle Scholar
    • 16  Usmani OS. Regional lung deposition and bronchodialator response as a function of β2-agonist particle size. Am. J. Respir. Crit. Care Med.172(12),1497–1504 (2005).
      MedlineGoogle Scholar
    • 17  Svartengren K. Added external resistance reduces oropharyngeal deposition and increases lung deposition of aerosol particles in asthmatics. Am. J. Respir. Crit. Care Med.152(1),32–37 (1995).
      Medline CASGoogle Scholar
    • 101  Weiner BB. What is particle size distribution weighting: how to get fooled about what was measured and what it means? (2011). www.brookhaveninstruments.com/pdf/What_is_Particle_Size.pdf
      Google Scholar
    • 102  de Koning JP. Dry powder inhalation: technical and physiological aspects, prescribing and use. Dissertation, University of Groningen. http://dissertations.ub.rug.nl/faculties/science/2001/j.p.de.koning/
      Google Scholar
    • 103  Al Habet S. NDA Application 21–868 Exubera Inhaled Insulin. Center For Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review Final, 52–54. www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021868s000_ClinPharmR.pdf
      Google Scholar
    • 104  Hovione. Dry powder inhalation devices. TwinCaps. www.hovione.com/inhalation/TwinCaps.pdf
      Google Scholar